v3.26.1
Document and Entity Information - shares
 12 Months Ended
Dec. 31, 2025
Mar. 08, 2026
Document Information [Line Items]    
Document Type 20-F/A  
Entity Registrant Name BioLineRx Ltd.  
Entity Central Index Key 0001498403  
Document Period End Date Dec. 31, 2025  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Amendment Flag true  
Document Registration Statement false  
Document Annual Report true  
Document Transition Report false  
Document Shell Company Report false  
Document Accounting Standard International Financial Reporting Standards  
Document Financial Statement Error Correction [Flag] false  
Entity's Reporting Status Current Yes  
Entity a Voluntary Filer No  
Entity Incorporation State Country Code L3  
Contact Personnel Fax Number 972 (8) 642-9101  
Entity Address, Address Line One 2 HaMa’ayan Street  
Entity Address, City or Town Modi’in  
Entity Address, Postal Zip Code 7177871  
Entity Address, Country IL  
Entity Interactive Data Current Yes  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus FY  
Entity Common Stock, Shares Outstanding   2,610,814,390
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity File Number 001-35223  
Entity a Well-known Seasoned Issuer No  
ICFR Auditor Attestation Flag false  
Amendment Description This Amendment No. 1 to Form 20-F (this “Amendment”) amends the annual report on Form 20-F of BioLineRx Ltd. for the year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission on March 23, 2026 (the “Original Report”). This Amendment is being filed solely to revise the consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited (“PwC”) included in Exhibit 15.1 of the Original Report. The consent included in the Original Report referenced the incorrect date of the report of PwC. A new consent of PwC is being filed as an exhibit hereto.   As required by Rule 12b-15 under the Exchange Act, as amended, new certifications by our principal executive officer and principal financial officer are being filed as Exhibits 12.1, 12.2, 13.1 and 13.2 to this Amendment.   This Amendment does not reflect events occurring after the filing of the Original Report and does not modify or update the disclosure therein in any way except as described above or herein. No other changes have been made to the Original Report. The filing of this Amendment should not be understood to mean that any statements contained in the Original Report, as amended by this Amendment, are true or complete as of any date subsequent to the original filing date of the Original Report.  
Business Contact [Member]    
Document Information [Line Items]    
Contact Personnel Name Philip A. Serlin  
Contact Personnel Email Address phils@biolinerx.com  
Entity Address, Address Line One 2 HaMa’ayan Street  
Entity Address, City or Town Modi’in  
Entity Address, Postal Zip Code 7177871  
City Area Code 972  
Local Phone Number 642-9100  
Entity Address, Country IL